Policy: MP335

Section: Medical Benefit Policy

Subject: Extracorporeal Photopheresis

I. Policy: Extracorporeal Photopheresis

II. Purpose/Objective:
   To provide a policy of coverage regarding Extracorporeal Photopheresis

III. Responsibility:
   A. Medical Directors
   B. Medical Management

IV. Required Definitions

   1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
   2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
   3. Devised – the date the policy was implemented.
   4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
   5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

   a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
   b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
   c. in accordance with current standards of good medical treatment practiced by the general medical community.
   d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
   e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

   (i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
   (ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
   (iii) The service or benefit will assist the Member to achieve or maintain maximum functional
capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

DESCRIPTION: Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory procedure that involves three steps. First, the patient’s blood is centrifuged to separate the leukocyte-rich portion from the rest of the blood; then the photosensitizer agent 8-methoxypsoralen is added to the lymphocyte fraction, which is then exposed to ultraviolet-A light at a dose of 1 to 2 J/cm². Lastly, the light-sensitized lymphocytes are reinfused into the patient.

INDICATIONS: Extracorporeal photopheresis may be considered medically necessary for any one of the following indications:

- Palliative treatment of skin manifestations of cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sézary syndrome) that are refractory to other therapy
- Acute or chronic graft versus host disease refractory to standard immunosuppressive drug treatment
- Acute cardiac allograft rejection refractory to standard immunosuppressive drug treatment
- Bone marrow transplant rejection or failure
- Stem cell transplant complications
- Bronchiolitis obliterans syndrome following lung allograft transplantation

FOR MEDICARE BUSINESS SEGMENT:
Per National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4), extracorporeal photopheresis may be considered medically necessary for any one of the following indications:

- Palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other therapy
- Patients with acute cardiac allograft rejection whose disease is refractory to standard immunosuppressive drug treatment
- Patients with chronic graft versus host disease whose disease is refractory to standard immunosuppressive drug treatment
- Extracorporeal photopheresis for the treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation only when extracorporeal photopheresis is provided under a clinical research study that meets the conditions outlined in NCD 110.4

EXCLUSIONS: The Plan does NOT provide coverage for the use of Extracorporeal photopheresis for any indication not listed in this policy because those applications are considered experimental, investigational or unproven. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established tests or technologies.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Extracorporeal photopheresis
The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

36552 Photopheresis, extracorporeal


LINE OF BUSINESS:
Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD’s will supersede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:
Center for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4).


This policy will be revised as necessary and reviewed no less than annually.

Devised: 03/20

Reviewed:

Reviewed: